Specificity of Food and Drug Administration postmarketing requirements and associations with timely submissions and regulatory decisions for oncology accelerated approvals, 2011–2023: a cross-sectional analysis
Objectives To assess the specificity of postmarketing requirement (PMR) statements and associations between PMR statement specificity and PMR study characteristics, timeliness and regulatory decisions.Methods and analysis This was a cross-sectional analysis of publicly available Food and Drug Admini...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-05-01
|
| Series: | BMJ Oncology |
| Online Access: | https://bmjoncology.bmj.com/content/4/1/e000659.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850271609133203456 |
|---|---|
| author | Steven Joffe Ronac Mamtani Ravi B Parikh Holly Fernandez Lynch William J Ferrell Martin Kurian Ernesto Ulloa Perez Rebecca Hubbard |
| author_facet | Steven Joffe Ronac Mamtani Ravi B Parikh Holly Fernandez Lynch William J Ferrell Martin Kurian Ernesto Ulloa Perez Rebecca Hubbard |
| author_sort | Steven Joffe |
| collection | DOAJ |
| description | Objectives To assess the specificity of postmarketing requirement (PMR) statements and associations between PMR statement specificity and PMR study characteristics, timeliness and regulatory decisions.Methods and analysis This was a cross-sectional analysis of publicly available Food and Drug Administration (FDA) databases to characterise PMR statements for oncology accelerated approvals (AAs) between January 2011 and July 2023. Characteristics of trials supporting AA and PMR studies were identified from product labels on the Drugs@FDA database and ClinicalTrials.gov. Main outcomes and measures included PMR statement characteristics, PMR study submission timeliness (on-time vs late) and regulatory decision (regular approval vs withdrawal).Results We analysed 181 PMR statements for 161 oncology indications. Most PMR statements specified target population (98%), endpoints (81% (44% included clinical endpoints; 37% surrogate endpoints only)), use of randomisation (63%) and comparator (54%). Fewer PMR statements specified a particular trial or protocol (45%), follow-up duration (30%), enrolment targets (26%), multicentre trial (24%), double-blinding (13%) or enrolment diversity (8%). PMR statements for indications granted regular approval were more likely than those for withdrawn indications to specify follow-up duration <1 year (27% vs 0%, p<0.001), allow endpoints other than overall or progression-free survival (27% vs 4%, p=0.01) and mention a specific trial or protocol (71% vs 36%, p=0.003). Compared to those submitted late, on-time PMR studies had fewer sites (110 vs 156, p=0.03), less use of blinding (20% vs 42%, p=0.02), more use of a continuous trial for AA and PMR (37% vs 8%, p=0.003) and more use of primary endpoints other than overall or progression-free survival (37% vs 6%, p<0.001).Conclusion PMR statement specificity for oncology AAs varies substantially. Less rigorous PMR statement and study characteristics were associated with timely PMR study submission and transition to regular approval but with important trade-offs. Given that AAs are granted without demonstrated clinical benefit, improving the balance between PMR study timeliness and rigour should be a priority when negotiating PMR statements. |
| format | Article |
| id | doaj-art-5c0f2e25bfc94c98b81b7cbefccc8496 |
| institution | OA Journals |
| issn | 2752-7948 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Oncology |
| spelling | doaj-art-5c0f2e25bfc94c98b81b7cbefccc84962025-08-20T01:52:11ZengBMJ Publishing GroupBMJ Oncology2752-79482025-05-014110.1136/bmjonc-2024-000659Specificity of Food and Drug Administration postmarketing requirements and associations with timely submissions and regulatory decisions for oncology accelerated approvals, 2011–2023: a cross-sectional analysisSteven Joffe0Ronac Mamtani1Ravi B Parikh2Holly Fernandez Lynch3William J Ferrell4Martin Kurian5Ernesto Ulloa Perez6Rebecca Hubbard7Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA4 Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USAEmory University Winship Cancer Institute, Atlanta, Georgia, USAassistant professor of medical ethics and lawPenn Center for Cancer Care Innovation, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USAHospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USAUniversity of Pennsylvania, Philadelphia, Pennsylvania, USAUniversity of Pennsylvania, Philadelphia, Pennsylvania, USAObjectives To assess the specificity of postmarketing requirement (PMR) statements and associations between PMR statement specificity and PMR study characteristics, timeliness and regulatory decisions.Methods and analysis This was a cross-sectional analysis of publicly available Food and Drug Administration (FDA) databases to characterise PMR statements for oncology accelerated approvals (AAs) between January 2011 and July 2023. Characteristics of trials supporting AA and PMR studies were identified from product labels on the Drugs@FDA database and ClinicalTrials.gov. Main outcomes and measures included PMR statement characteristics, PMR study submission timeliness (on-time vs late) and regulatory decision (regular approval vs withdrawal).Results We analysed 181 PMR statements for 161 oncology indications. Most PMR statements specified target population (98%), endpoints (81% (44% included clinical endpoints; 37% surrogate endpoints only)), use of randomisation (63%) and comparator (54%). Fewer PMR statements specified a particular trial or protocol (45%), follow-up duration (30%), enrolment targets (26%), multicentre trial (24%), double-blinding (13%) or enrolment diversity (8%). PMR statements for indications granted regular approval were more likely than those for withdrawn indications to specify follow-up duration <1 year (27% vs 0%, p<0.001), allow endpoints other than overall or progression-free survival (27% vs 4%, p=0.01) and mention a specific trial or protocol (71% vs 36%, p=0.003). Compared to those submitted late, on-time PMR studies had fewer sites (110 vs 156, p=0.03), less use of blinding (20% vs 42%, p=0.02), more use of a continuous trial for AA and PMR (37% vs 8%, p=0.003) and more use of primary endpoints other than overall or progression-free survival (37% vs 6%, p<0.001).Conclusion PMR statement specificity for oncology AAs varies substantially. Less rigorous PMR statement and study characteristics were associated with timely PMR study submission and transition to regular approval but with important trade-offs. Given that AAs are granted without demonstrated clinical benefit, improving the balance between PMR study timeliness and rigour should be a priority when negotiating PMR statements.https://bmjoncology.bmj.com/content/4/1/e000659.full |
| spellingShingle | Steven Joffe Ronac Mamtani Ravi B Parikh Holly Fernandez Lynch William J Ferrell Martin Kurian Ernesto Ulloa Perez Rebecca Hubbard Specificity of Food and Drug Administration postmarketing requirements and associations with timely submissions and regulatory decisions for oncology accelerated approvals, 2011–2023: a cross-sectional analysis BMJ Oncology |
| title | Specificity of Food and Drug Administration postmarketing requirements and associations with timely submissions and regulatory decisions for oncology accelerated approvals, 2011–2023: a cross-sectional analysis |
| title_full | Specificity of Food and Drug Administration postmarketing requirements and associations with timely submissions and regulatory decisions for oncology accelerated approvals, 2011–2023: a cross-sectional analysis |
| title_fullStr | Specificity of Food and Drug Administration postmarketing requirements and associations with timely submissions and regulatory decisions for oncology accelerated approvals, 2011–2023: a cross-sectional analysis |
| title_full_unstemmed | Specificity of Food and Drug Administration postmarketing requirements and associations with timely submissions and regulatory decisions for oncology accelerated approvals, 2011–2023: a cross-sectional analysis |
| title_short | Specificity of Food and Drug Administration postmarketing requirements and associations with timely submissions and regulatory decisions for oncology accelerated approvals, 2011–2023: a cross-sectional analysis |
| title_sort | specificity of food and drug administration postmarketing requirements and associations with timely submissions and regulatory decisions for oncology accelerated approvals 2011 2023 a cross sectional analysis |
| url | https://bmjoncology.bmj.com/content/4/1/e000659.full |
| work_keys_str_mv | AT stevenjoffe specificityoffoodanddrugadministrationpostmarketingrequirementsandassociationswithtimelysubmissionsandregulatorydecisionsforoncologyacceleratedapprovals20112023acrosssectionalanalysis AT ronacmamtani specificityoffoodanddrugadministrationpostmarketingrequirementsandassociationswithtimelysubmissionsandregulatorydecisionsforoncologyacceleratedapprovals20112023acrosssectionalanalysis AT ravibparikh specificityoffoodanddrugadministrationpostmarketingrequirementsandassociationswithtimelysubmissionsandregulatorydecisionsforoncologyacceleratedapprovals20112023acrosssectionalanalysis AT hollyfernandezlynch specificityoffoodanddrugadministrationpostmarketingrequirementsandassociationswithtimelysubmissionsandregulatorydecisionsforoncologyacceleratedapprovals20112023acrosssectionalanalysis AT williamjferrell specificityoffoodanddrugadministrationpostmarketingrequirementsandassociationswithtimelysubmissionsandregulatorydecisionsforoncologyacceleratedapprovals20112023acrosssectionalanalysis AT martinkurian specificityoffoodanddrugadministrationpostmarketingrequirementsandassociationswithtimelysubmissionsandregulatorydecisionsforoncologyacceleratedapprovals20112023acrosssectionalanalysis AT ernestoulloaperez specificityoffoodanddrugadministrationpostmarketingrequirementsandassociationswithtimelysubmissionsandregulatorydecisionsforoncologyacceleratedapprovals20112023acrosssectionalanalysis AT rebeccahubbard specificityoffoodanddrugadministrationpostmarketingrequirementsandassociationswithtimelysubmissionsandregulatorydecisionsforoncologyacceleratedapprovals20112023acrosssectionalanalysis |